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CHAPTER 1 
Introduction 
1.1. Preamble 
Chronic illness is detrimental to a patient’s quality of life both because of the symptoms 
of the illness itself, as well as the burden of treatment needed to combat the illness. The 
complexity of medical care today makes it difficult for healthcare providers to monitor a 
patient’s capacity to receive care even though treatment overburden can impact disease 
outcomes. We hypothesize that the healthcare system could use quantitative measures of 
treatment burden to evaluate the impact of disease and interventions on cancer patients. In this 
thesis, we propose a framework for quantifying burden of treatment in patients with breast 
cancer from electronic health record (EHR) data. We use this framework to evaluate treatment 
burden in a population of breast cancer patients and to detect changes in treatment burden with 
changes in therapeutic protocols. 
1.2. Minimally disruptive medicine 
In an era where patients are increasingly responsible for managing their own healthcare, 
minimally disruptive medicine is a new paradigm where providers ensure patients are able to 
adequately handle the care they are prescribed(1). Minimally disruptive medicine deals with the 
tension between two competing factors: A patient’s capacity to handle the work of receiving 
care, and the burden of their illness and treatment (2)(3). Several patient attributes help to 
increase their capacity to receive care. Personal, physical, emotional, social, environmental, and 
financial resources make patients more capable of achieving compliance with their treatment 
plans(4). For example, patients who have more financial resources, have access to transportation, 
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have flexible working hours, and who are literate will be more likely to handle more healthcare 
tasks(2).  
On the other hand, burden consists of the hardships imposed by illness and the work of 
receiving care for that illness(5). Burden of illness includes symptoms that reduce a patient’s 
ability to function such as fatigue, physical disability, or cognitive impairment(6). Burden of 
illness is typically well studied in medical literature. However, burden of treatment is not 
typically tracked or well understood in the medical community(7). Previous patient surveys have 
identified many factors that contribute to treatment burden and have categorized them in to three 
major themes: work patients must do to receive care, problem-solving and coordination, and 
factors that exacerbate perceived burden such as financial, emotional, and logistical 
challenges(8). Figure 1.1 illustrates the model of minimally disruptive medicine. A patient’s 
disease contributes both to the burden of the illness itself and treatment burden to counteract the 
disease. When burden exceeds a patient’s capacity to handle care, they are overwhelmed, 
typically leading to worsening outcomes. However, if patients are able to handle their care (ie. 
when capacity exceeds burden), they are able to fully comply with their treatment plan leading to 
positive health outcomes. Improved and worsening outcomes subtract and add respectively from 
burden causing a feedback loop that leads to recovery or increased morbidity. 
	 3	
 
Figure 1.1. Illustration summarizing minimally disruptive medicine.  
 
There is evidence that customizing care according to patient capacity is more than just 
making care convenient. A high burden can cause lower treatment plan compliance in patients 
with chronic diseases(9). Excessive treatment can also lead to wasted resources for the medical 
center, both from unnecessary procedures and from having to treat complications from 
noncompliance(10).  Physicians who practice minimally disruptive care assess burden and tailor 
treatment plans that give a patient the maximum likelihood of recovery while taking into 
consideration the patient’s limitations(1). To improve the effectiveness of this paradigm, 
providers and healthcare systems need reliable ways to identify overburdened patients and 
patient populations.  
1.3. Comparison to similar domains 
While itself a distinct research subject, burden of treatment has similarities to other 
healthcare research domains. Figure 1.2 shows the overlapping domains of quality of life, 
financial toxicity, burden of care and value-based medicine in relation to burden of treatment.  
One element of burden of treatment research that is not addressed in depth in any of these other 
domains is healthcare tasks. 
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Figure 1.2. Factors common to treatment burden and other similar domains 
1.3.1. Quality of life 
Perhaps the most well researched of these domains is quality of life. Quality of life scores 
are typically clinical measures that determine what loss in function, if any, occurred during and 
after a specific illness and associated treatment(11). Some quality of life scores are for general 
patient care such as the SF-36(12), while others are disease specific such as the DQOL for 
diabetes(13) and the EROTC QLQ for cancer(14). These quality of life scores focus on factors 
such physical, cognitive and social function, pain, fatigue, and other symptoms(15). In the 
minimally disruptive medicine paradigm, quality of life factors may influence burden of 
treatment, but they are more directly related to patient capacity and illness burden. 
There are some lessons from studies on quality of life that are applicable to our study of 
treatment burden. When studying quality of life, researchers have seen it is difficult to develop a 
single measure that adequately summarizes quality of life, since different patients may value 
return of different functions differently(16). When coming up with measures and treatment plans, 
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providers need to take into consideration patient preference and goals in order to accurately 
determine both quality of life and burden of treatment(17)(18)(19).  
1.3.2. Burden of care 
Although it sounds similar to burden of treatment, burden of care in medical literature 
refers to the burden that a patient’s illness imposes on their caretakers, especially with regards to 
elderly patients(20). For example, caretakers and family members of patients with cancer often 
experience depression, uncertainty about the future, and disruptions to home or work 
life(21)(22). Although burden of treatment is focused on the patient, many factors affect their 
caregivers. Patients with cancer often want to be with their family and caregivers during 
appointments requiring the patient to coordinate schedules and transportation(23). Especially for 
terminal diseases such as cancer, patients need to provide emotional support and financial 
planning, which increases the stress associated with their disease(21). 
1.3.3. Financial toxicity 
Another recently discussed topic with ties to treatment burden specific to cancer is 
financial toxicity. Similar to how toxicity from chemotherapy can lead to complications in their 
care, financial distress from having to pay for cancer treatments can cause increased risk for 
mortality(24). The problem has gotten so serious recently that scores have been developed to 
evaluate the extent of financial toxicity in cancer patients(25). While direct financial costs are 
one aspect of treatment burden, financial distress also contributes to capacity. For example, 
cancer patients without the financial capacity to afford a full course of oral chemotherapy could 
be non-adherent to their medication plan due to high co-pays(24). Additionally, patients who 
cannot afford their care may divert funds for other necessities and have to apply for government 
assistance such as food stamps and temporary disability(26). These patients may also ask people 
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they know for financial assistance or apply for grants, further adding to the work and emotional 
stress of being a patient. 
1.3.4. Value-based medicine 
In an effort to reform payment structures in the healthcare systems and contain costs, 
some have proposed outcomes based payment models as opposed to the traditional fee-for-
service models(27). Providers would be incentivized to maximize value of care by achieving all 
desired clinical outcomes while minimizing the cost of care to achieve those outcomes(28). 
Quality outcomes for breast cancer may include short term factors such as no nausea during 
chemotherapy, and long term outcomes such as remission and 5 year survival(28). While both 
value-based medicine and minimally disruptive medicine are focused on getting positive health 
outcomes, value-based medicine attempts to minimize costs to the healthcare organization 
without considering costs to the patient. It may be reasonable to conclude that decreased cost for 
healthcare systems translates to decreased burden for the patient. However, this correlation is not 
always clear. For example, in chemotherapy, oral regimens usually involve less time spent at the 
clinic than infusion regimens. However, there may be compliance or administration errors with 
home medications and the patient’s out of pocket expense is sometimes much higher with 
prescription co-pays versus infusions. In value-based medicine, there is no measure focused on 
the financial and workload costs to the patient. 
Nevertheless, attempts to implement value-based medicine may serve to decrease patient 
burden. With the current fee-for service model of healthcare, healthcare systems have incentive 
to perform as many procedures as possible, even if those procedures have little effect on 
improving outcomes, in order to maximize revenue. With value-based medicine on the other 
hand, healthcare systems are motivated to perform as few procedures as possible to achieve the 
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desired outcome to maximize their profit from their fixed payment. Value-based medicine could 
help align revenue incentives in a manner that decreases patient burden. 
 
 Figure 1.3. Aligning incentives for healthcare systems to positively affect patient burden. 
As such, the literature in minimally disruptive medicine and similar domains has started 
to characterize treatment burden. However, none of these studies have addressed a method to 
describe the extent to which healthcare tasks affect the work patients must complete. 
Additionally, previous scores meant to quantify factors similar to treatment burden have required 
patient reported data(15).  
1.4. Treatment burden in breast cancer 
Breast cancer patients often undergo intense, multi-modal treatments resulting in 
diminished quality of life(29)(30). Unlike diseases previously studied for burden of treatment 
like diabetes, cancer care is more episodic. These care episodes can require intense treatment 
over the course of months and years(31). A nationwide study showed that among patients 
undergoing chemotherapy and radiotherapy, 28% had to schedule appointments to treat side 
effects, 77% had to arrange for caregivers to accompany them to their appointments, and 43% 
had some impact on their professional lives(31). Additionally, oncology patients are typically 
older and have many comorbid conditions that add to the complexity and burden of 
treatment(32). 
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One reason why burden of treatment measures are needed in breast cancer care is because 
of the many choices patients have for treatment paths. After diagnosis, providers must discuss 
with patients the benefits and risks of different treatment options such as surgery (lumpectomy or 
mastectomy), radiation therapy, chemotherapy, immunotherapy, hormone therapy, or some 
combination of these(33). Some of these options may have clear therapeutic advantages for 
certain patients. However, when deciding between options like lumpectomy with radiation and 
mastectomy that have similar survival rates(34), it may be unclear which of these choices would 
burden the patient less in the short term with treatment, and in the long term with complications 
and recurrence. In previous studies, treatment decisions for patients with breast cancer were 
significantly influenced by the frequency of the care and how specific (i.e. quantitative) 
information given by the provider was(35). We believe that a quantitative approach for assessing 
treatment burden could inform interventions to help minimize treatment burden for patients with 
breast cancer. 
1.5. Measuring burden and capacity 
Previous research on the topic of treatment burden has focused on surveys to create 
scores for patient work, and to create a framework for researching and delivering minimally 
disruptive medicine(36). In an online survey of 1053 patients, researchers created a taxonomy of 
factors that contribute to the burden of treatment including healthcare tasks and situational 
factors that exacerbate a patient’s work (37)(38). Tran et. al. also developed and validated the 
Treatment Burden Questionnaire (TBQ), a survey instrument designed to assign an global score 
for treatment burden(38)(39). Some of the items on the TBQ address healthcare tasks themselves 
such as the number of times patients must take their medication per day, or the frequency and 
duration of doctors’ visits and lab tests. Other factors are more subjective such as the impacts of 
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healthcare on social relationships or how often healthcare reminds the patient of their health 
problems. The group that developed TBQ showed that their global score was significantly 
correlated with quantitative measures workload variables such as number of hospitalizations in 
the last year, number of different physicians, number of medication tablets taken per day, and 
number of medical appointments per month. Disease specific questionnaires have also been 
developed to assess the burden of treatment in specific chronic conditions such as chronic heart 
failure(40), post stroke(41), and end stage renal disease requiring dialysis(42). While these 
surveys are effective in defining treatment burden, they still rely on patient reported surveys for 
their data, which would not enable large scale population studies of burden or automated 
monitoring to identify overworked patients who may need intervention. 
One factor of treatment burden that is being quantified in public health informatics is 
with study of healthcare access. Using Geographical Information Systems (GIS), public health 
informatics studies have calculated driving distance to the nearest medical center and attempted 
to correlate geographic factors to healthcare utilization such as mammogram screening for breast 
cancer patients(43). Similarly, burden of treatment studies will be able to use GIS software to 
determine the commute time to and from the medical center for procedures as a major 
contributor to the work patients must put into their care. 
A recent study also sought to quantify the counterweight to burden, capacity. Boehmer et. 
al. used a bevy of previously developed psychosocial metrics to assess capacity in 137 patients 
on dialysis(4). Some of these surveys include CD-RISC-2 for patient resilience, SF-36 for 
emotional well-being, PROMIS Short Form 4a for social capacity, and the CAHPS Patient 
Health Care Home Survey for environmental capacity. They correlated these capacity factors 
with illness intrusiveness and found that physical, emotional, and financial well-being were most 
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important for patients to feel they were in control of their treatment. Developing an automated 
method to quantify capacity may be a challenge due its subjective nature. Whether patient 
reported or derived from the EHR, it is essential for future work to complement burden measures 
with capacity metrics so that providers can balance the two for patients leading to better 
outcomes. 
1.6. Anomaly detection in healthcare 
One important use for treatment burden measures is to identify outliers who may require 
help managing their care. Healthcare organizations have used anomaly detection in public health 
for disease surveillance. For example, the University of Alabama developed a method to quickly 
identify hospital acquired infections from laboratory data by identifying patterns of transmission 
that may not be immediately evident to healthcare providers(44). A Pittsburgh based team also 
used rule-based anomaly detection to identify disease outbreaks based on patterns in clinical data 
in local emergency rooms(45). In both cases, anomaly detection enabled the respective 
healthcare systems to identify outliers that required intervention but that were difficult for 
healthcare professionals to notice. Similarly, patients experiencing high treatment burden may 
not be immediately identified by their providers, especially if these appointments span multiple 
departments. 
Researchers have also used outlier detection methods to scan clinical trial reviews for 
significant relationships between chemotherapy drugs and adverse events(46). Lou and Cisler 
used boxplots to visualize the distribution of incidences of adverse events by common 
chemotherapy drugs from clinical trial literature. Using Grubbs’ test, they identified drugs where 
the association with a given type of adverse event was significantly higher than other drugs. 
Using this outlier detection method, this study successfully aggregated previously published data 
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from a large set of publications to discover novel associations without having to conduct any 
additional clinical trials. With treatment burden research, it is possible to prospectively collect 
data from patients about their healthcare tasks during their cancer care as studies have done in 
the past(31). However, our study proposes that the data already existing in various sources in the 
EHR would allow us to assess burden of treatment in many patients with cancer. 
Anomaly detection is also used by providers to identify high-risk patients. Many studies 
have attempted to develop models that predict hospital readmissions(46). Readmissions are of 
interest to payers and healthcare organizations due to their financial cost the hardship they place 
on patients. Patients who have high treatment burden in both the inpatient and outpatient setting 
also endure disruptions to their personal lives and financial costs. Having a tool that flags 
overburdened patients could be useful to identify those patients quickly and to intervene 
accordingly. 
1.7 Interventions related to treatment burden 
Treatment burden measures derived from the electronic medical record would be useful 
for evaluating the effectiveness of new treatment protocols or healthcare operations interventions 
that aim to reduce treatment burden. These measures could also assist with patient and provider 
treatment plan decisions. To enable the practice of minimally disruptive medicine, healthcare 
systems could leverage informatics methods that use medical record data to make burden of 
treatment data useful for the healthcare delivery team. One of the uses of EHR data is to enable 
retrospective and prospective comparative effectiveness research(47). Before EHRs were 
available, researchers would have to set up a clinical trial to compare different treatments, which 
required recruiting patients, setting up controls and in-person follow-ups with patients. EHRs 
enable researchers to collect that data passively through records already stored electronically for 
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patient care, often with no disruption to the provider or patient. EHRs also enable comparative 
studies that investigate previous protocol changes with the rapid collection of a large number of 
patients(48). 
 A treatment burden measure would be useful when assessing treatment options in clinical 
trials. Historically, trials in cancer compare clinical outcomes such as disease free survival and 
recurrence(49). In recent clinical trials, researchers have shown that pathological complete 
response, which is the absence of cancerous tissue after treatment, is correlated to disease-free 
and overall survival(50). Since pathological complete response can be evaluated immediately 
after treatment, it has become the standard measure in determining therapeutic efficacy in breast 
cancer clinical trials(51). Clinical trials also document patient-reported outcomes such as 
anxiety, physical function, pain, and fatigue(52). With chemotherapy, clinical trials report 
commonly occurring side effects from toxicity such as diarrhea, alopecia, leukopenia, 
thrombocytopenia and neutropenia(53)(54)(55). We believe that burden of treatment is also an 
important measure that should be incorporated into clinical trials. As discussed, the work of 
receiving care can have an impact on patient burden just as illness and side effects do. In Chapter 
4 of this thesis, we demonstrate a method of comparing treatment burden for chemotherapy 
protocols that could be replicated for clinical trials. 
The ultimate goal of our research is to positively impact the delivery of healthcare. We 
want to enable providers to practice minimally invasive medicine by developing tools that weigh 
treatment plans against patients’ capacity to handle that treatment. Clinical decision support 
systems process electronic health record data and present information through calculators, alerts, 
and reminders to healthcare providers(56). Although the creation of a clinical decision support 
tool for treatment burden assessment is beyond the scope of this work, it is important for us to 
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consider how to develop measures and analyses for treatment burden that are useful for 
clinicians. As such, it is important to consider how to implement and evaluate the impact of 
integration of a quantitative measure of treatment burden within the context of the workflow of a 
healthcare delivery team with the goal of providing decision support to minimize treatment 
burden. Additionally, we must design any patient-facing tools such as mobile applications that 
help patients monitor or cope with burden in such a way that they are useful to patients(57). 
Healthcare organizations could use treatment burden measures to evaluate the efficacy of 
healthcare operation interventions. Hospitals have tried to implement lean practices borrowed 
from the automotive industry as a way to increase efficiency and improve quality(58). Lean 
management requires collection of clinical and administrative data like clinic throughput, and 
medical errors(59). Hospitals have used logistics methods such as scheduling optimization in 
chemotherapy(60) and other healthcare settings to maximize provider utilization(61). While 
these methods have been shown to improve operations in the medical center, they should also be 
evaluated for how they impact work for the patient. 
 Burden of treatment also plays a part in defining the successes or failures of precision 
medicine. Initiatives in precision medicine seek to tailor treatment strategies to take into 
consideration individual variability in genetic, clinical, environmental, and molecular 
factors(62). The paradigm of minimally disruptive medicine uses some concepts from precision 
medicine in that providers need to tailor the amount of care given based on characteristics of the 
patient that show they have the capacity to handle the care. However, an even more powerful 
application of a burden of treatment measures is to assess changes in practice championed by 
precision medicine for their effect on patient work. Precision medicine research in breast cancer 
has identified biomarkers that make the cancer vulnerable to certain targeted therapies(63). 
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These targeted therapies are more effective and require fewer treatments for the patient(64). In 
order to quantify the effect of these precision medicine diagnostics on the patient experience, the 
healthcare community needs burden of treatment measures. 
	 15	
CHAPTER 2 
Quantitative Measures for Treatment Burden from Encounter Data 
2.1. Introduction 
This chapter proposes a method to quantify one of the more reliable contributors to 
treatment burden in patients with breast cancer: clinical encounters. While appointments only 
contribute to part of a patient’s overall treatment burden, time and effort spent coordinating, 
traveling for, and waiting for care were among the most commonly mentioned contributors to 
burden in a survey of 1053 patients with chronic disease(37). Among these patients who 
responded to an online survey, 50% mentioned that some burden stemmed from treatment 
appointments and follow-up compared to 29% who felt burdened by paperwork and 13% that 
mentioned learning about their condition. The majority of patients were also burdened by 
managing medications and lifestyle changes such as diet changes, exercise, and quitting 
smoking. In the treatment burden questionnaire (TBQ), encounter related burden factors were 
among the most highly correlated with the overall TBQ score(39). Unlike diabetes where most 
care is performed by the patient away from the medical center, cancer care is highly dependent 
on procedures (such as chemotherapy, radiotherapy, and surgery) that are well captured by 
outpatient encounters. Hospital admissions are also of interest to patients and hospital 
administration. Admissions are frequent and often unexpected in patients with cancer (65). 
Although inpatient time was typically not mentioned in previous burden of treatment literature, 
admissions are disruptive to patients and their caregivers.  To our knowledge, no previous studies 
have used data from electronic health records (EHRs) to assess treatment burden in patient 
populations. By using appointment and admission data, our evaluation of treatment burden is 
reliable, reproducible, and scalable given accurate electronic records. 
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2.2. Healthcare tasks in the EHR 
 
Figure 2.1. Relative completeness and structure of data elements related to factors of healthcare 
tasks. Highly structured and complete elements may be amenable to automated extraction and 
quantification from the electronic health record.   
 
Research using EHR data is most effective when that data is structured and 
complete(66)(67). Figure 2.1 displays several healthcare tasks identified by Tran et. al.(37) and 
Eton et. al(36). For tasks with data available in the EHR, we evaluated them for approximate 
completeness and structure of data in the EHR. Treatment burden elements in the top-right 
quadrant of Figure 2.1 such as clinic visits and medications are both highly structured and highly 
complete by virtue of their relation to billing. These top-right elements are more reliable 
measures than elements in the bottom-left that are unstructured and less available. For example, a 
patient’s exercise program is less likely to be captured in an EHR but may be recorded in other 
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systems managed by the patient outside the EHR. While healthcare institutions may differ in 
how these factors of treatment burden are recorded, many of these data elements are available 
across different implementations of clinical information systems. 
2.3. Burden of treatment measures 
Our goal was to create and evaluate several measures of treatment burden derived from 
appointment records. Since we are interested in the complete burden patients experience, we 
collected encounter data for all types of appointments, including non-cancer related encounters, 
from the start to the end of their care episode. The measures derived from the encounter record 
represent different aspects of burden that patients experience as part of their care. We extracted 
outpatient appointment data from the Epic scheduling system that had been in use at Vanderbilt 
University Medical Center (VUMC) since 1997.  Hospital admission and discharge data was 
extracted from the Medipac system with data going back to 1984.  
2.3.1 Appointment time  
Our first measure of treatment burden was total appointment time. We calculated the time 
spent in appointments as the sum of the lengths of all appointments over a given time period. 
Time spent in appointments requires a high level of activity by the patient. Patients receiving 
breast cancer treatment in our study underwent not only cancer related procedures such as 
chemotherapy infusions and radiation therapy but also imaging procedures, laboratory draws, 
and non-oncology appointments. Appointment time represents their direct interaction with the 
healthcare system. 
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Figure 2.2. Burden of treatment measures for an example patient. This example breast cancer 
patient had about 9 hours of appointments, 11 appointments, 2.25 hours of waiting, 11.25 total 
hours in clinic, and 7 unique appointment days over two weeks chemotherapy treatment. MO= 
Medical Oncologist, Inj = Injection clinic, NP = Nurse Practitioner,  
 
2.3.2 Appointment count 
Appointment count was another measure that represented a similar but distinct dimension 
of treatment burden. We counted the number of appointments over the course of each patient’s 
care episode. Each individual appointment is a unit of work the patient must perform. Every 
individual appointment has associated tasks such as checking in at reception, waiting for the 
appointment to begin, and engaging with providers and other staff. 
2.3.3 Wait time 
We extrapolated that wait time was the time between scheduled appointments if a patient 
had more than one appointment in a given day. Time spent waiting between appointments 
represents wasted time for the patient. Some wait time is necessary for upstream dependencies 
for treatment. For example, the laboratory needs time to process blood samples to determine 
whether a patient can receive chemotherapy. However, this time brings no value to the patient 
and can cause anxiety and frustration for patients while waiting to receive care.  
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2.3.4. Total time in clinic 
To approximate the total time spent in clinic including waiting time, if a patient had more 
than one appointment in a day, we calculated the time from the beginning of the first 
appointment to the end of the last appointment of the day. Although derived from appointment 
time and wait time, the total time patients spend in clinic captures another dimension of 
treatment burden. Patients and their caregivers who continue their employment during treatment 
must request time off in at least the amount of their total time in clinic. If patients are caring for 
family members, they may need to request substitutes or hire professional caregivers during the 
time they are receiving care.  
2.3.5. Unique appointment days 
Unique appointment days represent the work of coordinating and commuting to the 
clinic. Patients who receive cancer care often request friends or family join them, which places a 
burden on the patient to coordinate schedules. For patients who do not leave home often, each 
unique appointment day adds to the stress and effort of getting ready to leave home and traveling 
to the medical center.  
2.3.6 Admissions 
We also collected data on whether patients were admitted to the emergency room or 
inpatient unit sometime over the course of treatment, and their overall length of stay during those 
admissions. Some admissions are planned, such as those for immediate post-operative 
monitoring, while other admissions may be related to severe health complications from the 
patient’s underlying disease or their cancer treatment, such as uncontrolled nausea and vomiting 
from chemotherapy toxicity(55). Patients who are admitted during their care episode experience 
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the highest level of potential health risk and disruption to patients’ daily lives and so changes in 
treatment protocol should look to minimize complications that lead to admissions.  
2.4. Discussion 
Using the appointment record at VUMC has limitations. While the appointment record 
should be accurate and complete due to its association with billing, it does not always reflect 
exactly what happened in the clinic. For the purpose of this study, time between appointments is 
a heuristic for actual wait times. Our method of determining the amount of time spent in clinic is 
a conservative estimate. It does not take into consideration situations where patients arrive early, 
appointments start late, patients leave between appointments, or appointments end earlier than 
the time allotted. Using data from systems that track patient arrivals, departures, and movements 
within the clinic, such as VUMC’s outpatient whiteboard(68), could enable more detailed 
analysis of patients’ total time in clinic.   However, since these systems rely on manual updates 
of patient movements, they could have limited accuracy.  To address this, some healthcare 
systems have reported use of real time locator systems (RTLS) to pinpoint the location of 
patients as they move through the medical center(69). These advanced techniques could provide 
more precise data about patient burden during patient encounters, but would be difficult to 
generalize to other institutions that do not have similar infrastructures for patient tracking. 
Another limitation of using only VUMC’s encounter data is that most patients do not receive all 
of their care at a single institution.  Our approach acknowledges this, and appreciates that this 
may account for a large range of treatment burden among patients with similar diagnoses.   
Despite these limitations, a major advantage of this approach for assessing burden of 
treatment is its simplicity of calculation and generalizability to other healthcare organizations 
who all have electronic appointment and admission records. Since Stage 1 Meaningful Use was 
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enacted, healthcare systems are incentivized to maintain accurate patient encounter records(70). 
Therefore, any healthcare organization could use scheduling data to approximate patient burden. 
On the other hand, some limitations impede direct comparisons between our study population 
and those at other institutions. Other institutions may record appointments differently than 
VUMC. For example, another healthcare system with the patient in Figure 2.2 could have just 
one very long appointment that incorporates the lab, medical oncologist, and infusion visits. 
Meanwhile at VUMC, each of those encounters is recorded as a separate appointment. 
Comparing patient populations within that institution would still be possible but comparing 
certain features of treatment burden across institutions might be challenging.  
2.5 Conclusions 
 Treatment burden measures derived from encounter data only capture one aspect of the 
work that patients need to perform to receive care. Nevertheless, factors such as total time in 
clinic, unique appointment days, and admissions represent a large portion of burden, particularly 
for cancer patients. These factors derived from electronic appointment records are also highly 
complete and reliable making this method generalizable at other institutions. 
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CHAPTER 3 
Evaluating Treatment Burden in Breast Cancer Patient Subpopulations 
3.1 Introduction 
A useful quantitative measure of treatment burden must be able to differentiate between 
patient populations that are expected to have differences in their intensity of treatment. To 
evaluate this capability of our measures, we applied them to a population of breast cancer 
patients with early stage (I-III) disease.  Breast cancer patients at Vanderbilt with stage III 
disease typically have much more intensive, multimodal treatment than those with stage I or 
stage II disease.  We thus hypothesized that patients with stage III cancer would have a higher 
treatment burden than patients with stage I or stage II cancer given the more aggressive therapy 
they receive for higher risk disease. Breast cancer treatment given with curative intent is 
typically delivered within the first 18 months after diagnosis. Therefore, we likewise 
hypothesized that the burden of treatment would be greatest in the first few months after the date 
of cancer diagnosis, and that this burden would decrease over time.  
3.2 Methods 
We applied the treatment burden metrics described in Chapter 2 to a population of breast 
cancer patients at Vanderbilt University Medical Center (VUMC). The goal of this analysis was 
to investigate whether there was differentiation in number of appointments, appointment time, 
wait time, total time spent in clinic including wait time, number of admissions, and total inpatient 
length of stay between breast cancer patients with stage I, stage II, and stage III disease. 
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3.2.1. Study population 
The patient cohort for this study was chosen from the VUMC Cancer Registry since those 
were the patients who were diagnosed and receive all or part of their first course of treatment at 
our institution. We collected 18 months of encounter information from all stage I-III breast 
cancer patients who were diagnosed over a 17-year period between January 1, 1998 and June 1, 
2014. To facilitate comparison between sub-populations of patients that received the majority of 
their care at our institution, we included only patients with at least three appointments from both 
a Vanderbilt medical oncologist and a Vanderbilt surgical oncologist in the first 18 months after 
diagnosis. We determined which appointments were with a medical or surgical oncologist by 
mapping their national provider identification number with their specialty in the national patient 
identifier (NPI) data dissemination file(71).  
Among the 8161 patients with breast cancer in the VUMC Cancer Registry, 5661 had a 
date of diagnosis between January 1, 1998 and June 1, 2014. Among these, 4152 patients had 
stage I-III disease at diagnosis. After collecting 18 months of appointments after the date of 
diagnosis for these patients, we found that 904 had more than three appointments with a medical 
oncologist and a surgical oncologist at VUMC (Figure 3.1).   
 
 Figure 3.1. Cohort selection 
3.2.2. Analysis 
We compared the distributions of each treatment burden measure over 18 months by 
stage.  We used an Kruskal–Wallis H test to see if there was a significant difference between 
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stages I-III for each of these metrics. We compared the estimated time spent in clinics by month 
over 18 months by stage. We also plotted the time spent in appointments by department for all 
patients over 18 months. The Vanderbilt Institutional Review Board approved this study and 
granted a waiver of consent since we analyzed a large population of patients in aggregate (IRB 
#151003).  
3.3. Results 
Table 3.1 summarizes the clinical encounter burden by stage.  Among the 904 patients in 
the final cohort, 419 had stage I, 337 had stage II, and 148 had stage III disease. Across all 
stages, the median patient in our cohort had 59 appointments on 39 unique appointment days, 
spent 2.7 hours in clinic per month, and was never admitted over the 18 months after diagnosis. 
The median stage III patient had the greatest number of appointments (88), the greatest amount 
of time spent in clinic per month (5.4 hours), and the greatest number of hospitalized days (1.2). 
Stage II patients had the second greatest totals in each of these parameters and stage I patients 
had the least. The H tests for all of the metrics were significant with p-values less than .001.  
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Table 3.1. Summary of clinical encounter burden for breast cancer patients by stage with H test 
p-values comparing the difference between stage I, stage II, and stage III. 
Treatment Burden Factor by  
Breast Cancer Stage 
Stage I Stage II Stage III Stage I-III 
H test 
p-
value 
       Number of patients 419 337 148 904 N/A 
In
 fi
rs
t 1
8 
m
on
th
s a
fte
r d
ia
gn
os
is
 M
ed
ia
n 
(I
Q
R
) 
Number of 
appointments 48 (27-71) 69 (44-97) 
88 (52-
125) 59 (35-89) < .001 
Unique appointment 
days 34 (17-54) 43 (26-64) 49 (30-85) 39 (22-61) < .001 
Hours of 
appointment time 20 (12-32) 41 (23-67) 60 (37-83) 30 (16-58) < .001 
Hours spent waiting 
between 
appointments 
13 (8-23) 25 (14-40) 33 (19-50) 19 (10-34) < .001 
Hours spent in clinic 33 (21-55) 67 (38-107) 
97 (58-
129) 49 (28-94) < .001 
Hours spent in clinic 
per month 
1.8 (1.2-
3.1) 
3.7 (1.9-
5.9) 
5.4 (3.2-
7.2) 
2.7 (1.6-
5.2) < .001 
Number of unique 
admissions 0 (0-1) 1 (0-1) 1 (1-2) 0 (0-1) < .001 
Total inpatient length 
of stay (days) 0 (0-1.2) .13 (0-2.5)  1.2 (0-4.5) 0 (0-2.2) < .001 
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Figures 3.2 and 3.3. Distribution of total number of appointments over 18 months by breast 
cancer stage (H test p-value <.001), and total time in clinic over 18 months by breast cancer 
stage (H test p-value <.001). The dark horizontal line for each boxplot represents the median and 
the colored box represents the interquartile range (IQR) (25th to 75th percentile). The “whiskers” 
extend to 1.5 times the IQR or to the minimum or maximum value, whichever is closer. Any data 
points outside the whiskers are outliers and are represented individually as circles. 
 
The boxplot in figure 3.2 further shows that the median and interquartile ranges of the 
number of appointments is greatest for patients with stage III disease followed by stage II and 
stage I.  There were five outliers for stage I patients with an unusually high number of 
appointments while there were two outliers for stage II patients. Figure 3.3 shows that the 
median time spent in clinic was greatest for stage III patients followed by stage II and stage I. 
There are twenty-six outliers for stage I patients in time spent in clinic and two for stage II 
patients. 
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Figure 3.4. Total time spent in clinic by breast cancer stage over 18 months 	
 
Figure 3.5. Appointment time by department over 18 months for all patients 
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Over the course of 18 months after diagnosis, the average total time spent in clinic per 
patient decreased (figure 3.4). In the first month of treatment, stage I patients spent on average 8 
hours in clinic while stage II and III patients spent 10 and 12 hours respectively. All three stages 
saw a decrease in time spent in clinic in the second month but then had an increase in the third 
and fourth months. In each month after diagnosis, the average time spent in clinic was greater for 
stage III than stage II or stage I breast cancer patients, although this difference was not 
statistically significant for any given month. Figure 3.5 shows that radiology imaging 
appointments made up a significant portion of appointment time in the first couple months and 
decreased rapidly after date of cancer diagnosis. Infusion appointments made up the majority of 
appointment time from 3-7 months after diagnosis. Medical, surgical, and radiation oncology 
appointment times were greatest first six months after diagnosis and tapered as time went on. 
3.4. Discussion 
The boxplot in figure 3.2 is a good example of how healthcare systems can use 
appointment data as a proxy for treatment burden to identify outliers. In our population, a 
provider would notice that there are five stage I patients who had around 150 appointments in an 
18-month period. A patient care team for one of those patients could investigate whether the 
appointments are appropriate. If that care is necessary, the healthcare system may look into ways 
to help ameliorate burden such as home visits or transportation assistance.  
Understanding treatment burden can aid in delivering the right amount of care that is 
prioritized to what each individual can handle. When patients are newly diagnosed with stage I-
III breast cancer, Figure 3.3 could help them anticipate how much time they will need to devote 
to coming to receive care and how much time they will need to take off from work. Future work 
could further divide our cohort into patients who chose different treatment paths such as 
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prophylactic contralateral mastectomy followed by reconstruction compared to lumpectomy with 
radiation therapy. Showing the treatment burden of similar patients could help educate patients 
about treatment options and their trade-offs.  
Focusing on outliers in appointment burden could also identify opportunities for 
improved care coordination and more convenience for the patient. For stage I patients in figure 
3.3, there are many more outliers for total time spent in clinic than for count of appointments in 
Figure 3.2. Since Figures 3.2 and 3.3 visualize the same population of patients, an increase in the 
number of outliers means that some patients who are outliers in time spent in clinic either have 
longer appointments or more time between their appointments. These patients would be 
candidates for care coordination interventions such as arranging their appointments closer 
together on the same day, or assigning them to a medical home clinic. 
Figure 3.5 is an example of a visualization that healthcare organizations could use for 
resource planning. For every patient diagnosed with breast cancer this month, we can predict that 
the infusion center will need to have space, equipment, and staffing for an infusion chair for 2-3 
hours three months from today. For resource constrained departments such as radiation therapy, 
knowing when patients diagnosed today will require their services could help them to prepare the 
staffing and other resources necessary for the increased demand. 
There were several potentially confounding factors that we attempted to control for in our 
cohort selection. The first and most significant is that we had to determine which patients 
received their first course of treatment at VUMC. Although the cancer registry had information 
about which providers saw patients in the registry and what institutions they were from, the 
availability of that data was inconsistent. We decided on a data driven approach where we 
defined patients as having received their first course of treatment at VUMC if they had at least 
	 30	
three appointments with both a medical oncologist and surgeon from VUMC in the first 18 
months of treatment. This constraint cut our cohort by more than 75%, but enacting the 
constraint was necessary to ensure that analysis focused on patients receiving care where we had 
more complete data on their encounters. We limited our analysis to stage I-III patients for a 
similar reason. Stage 0 and incurable stage IV patients have very different patterns of care 
making them less comparable in the first 18 months of treatment to stage I-III patients.  We 
chose 18 months as the interval for analysis since a typical course of treatment occurs within that 
time frame and there is a very low risk of disease recurrence during this time(72).  
Another limitation of this study is that we were not able to address missing data from 
patients lost to follow-up during the 18-month time span, or for care patients received outside of 
our institution. Furthermore, during the 17-year period where we observed our patients, there 
were changes in the way appointments were recorded in the system. There was a gradual 
increase in appointments per patient due to an increased number of departments using the 
scheduling system. The effect of this increase in appointment capture should have been minimal 
on the analysis since they would be equally distributed across patients in the different stages. 
3.5. Conclusions 
By describing and visualizing burden of treatment in a population of breast cancer 
patients, we believe this study helps providers deliver minimally disruptive medicine by 
identifying outliers who may need interventions to help decrease their burden. Quantifying 
burden of treatment for a given disease would also be useful for educating patients who are 
newly diagnosed so that they are prepared for the work ahead of them. Additionally, 
understanding the trend of utilization by department allows healthcare systems to ensure 
resources are available for future treatments at the time a patient is diagnosed. 
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CHAPTER 4 
Evaluating Burden of Treatment with Changes in Chemotherapy Protocol 
 
4.1 Introduction  
New developments in treatment protocols have increased patient survival across all 
cancer types since the 1990s(73). As survival improves, patients could be more concerned with 
the convenience and quality of their care. In cancer treatment, there are many choices that 
patients and providers have to make based on the patient’s disease and goals(17). Providers 
could use treatment burden measures to compare two or more treatment protocols for their 
impact on patients. Advertisements for medical services and medications often tout treatment 
burden reducing potential by “saving you a trip to the doctor” or needing just “one pill a day”. 
Nevertheless, these claims are not typically substantiated with quantitative assessments of patient 
experience. Patients, healthcare providers, and healthcare delivery systems, need a method to 
track the patient work associated with cancer care to better inform treatment decisions. 
Additionally, changes in treatment protocols need to be evaluated for how they impact treatment 
burden. 
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Figure 4.1. Change in treatments are desirable if they are clinically more effective and reduce 
the burden of treatment. 
 
This chapter details whether quantitative measures of treatment burden are sensitive to 
subtle changes in chemotherapy treatment protocols. We apply our methods of quantitative 
measurement of treatment burden to a retrospective cohort of early stage breast cancer patients 
receiving neoadjuvant or adjuvant infusion drug therapy. In doing so, we demonstrate that a non-
inferior therapy can decrease treatment burden, and that a therapeutically superior treatment 
strategy may increase treatment burden beyond expectations. 
The introduction of the on-body-injector (OBI) for the granulocyte colony-stimulating 
factor, pegfilgrastim (Neulasta) is an example of a protocol change that is clinically non-inferior 
but may decrease treatment burden. Neulasta is given by subcutaneous injection 24 to 72 hours 
after chemotherapy to increase neutrophil production and decrease the risk of infection and 
febrile neutropenia(74)(75). Patients receiving Neulasta via subcutaneous injection either have to 
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return to the infusion clinic the day after their chemotherapy to receive the injection(76), or self-
administer the injection at home. In contrast, an OBI is a device that is attached to the patient 
during their infusion appointment and programmed to automatically inject medication at a time 
specified by the provider(77).  
A previous study showed that pegfilgrastim administered via OBI was clinically non-
inferior to subcutaneous injection(78). The study used serum concentration over time and 
adverse event occurrence to determine that the two modes of Neulasta administration were 
equally effective. While the authors may have implied that using the OBI would decrease work 
patients must do, there was no empirical evidence showing that the OBI actually benefited any 
patients. Therefore, this clinical trial could have strengthened its conclusions about the benefit of 
using the OBI by showing the difference in treatment burden between patients who received 
Neulasta through the OBI versus those who received Neulasta through a subcutaneous injection. 
Starting in January 2015, the Vanderbilt Cancer Center made Neulasta OBI available in place of 
the subcutaneous injection, thus obviating the need for the patient to return to the infusion clinic 
the day after chemotherapy or complete the approval process to take the drug home. We 
hypothesize that patients who started a given chemotherapy regimen with the Neulasta OBI 
would have fewer unique appointment days compared to patients who received in-clinic 
subcutaneous Neulasta. If the burden of treatment is reduced, the transition to using the OBI 
instead of the next day subcutaneous injection is a desirable change. 
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Figures 4.2 and 4.3. Neulasta OBI is non-inferior to the subcutaneous injection of Neulasta but 
may reduce treatment burden. TCH with pertuzumab a clinically superior treatment but may 
increase patient burden.  
 
The addition of pertuzumab to docetaxel, carboplatin, and trastuzumab (TCH+P) 
chemotherapy protocols for patients with HER2-positive breast cancer is an example of a 
therapeutically superior treatment that may significantly increase treatment burden. Pertuzumab 
is a monoclonal antibody that complements trastuzumab by inhibiting ligand-dependent 
signaling between HER2 and HER3, thus inhibiting cell division(79). Clinical trials for 
pertuzumab showed that pathological complete response increased to 66% for patients receiving 
neoadjuvant TCH+P(80) compared to just 39% pathological complete response in patients who 
received just docetaxel, carboplatin, and trastuzumab (TCH)(81).  
While these clinical trials showed that the addition of pertuzumab was therapeutically 
superior, it increased toxicity by adding another infusion medication. The percentage of patients 
with decreased left ventricle ejection fraction did not differ much between TCH and TCH+P, but 
patients receiving TCH+P experienced an increase incidence in most grade 3 or 4 side effects 
compared to TCH including neutropenia, leukopenia, diarrhea, and vomiting(80)(81). Although 
readers can infer that grade 3 and 4 adverse events from chemotherapy toxicity would require 
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some follow-up care, these studies do not state the increased treatment burden for adding 
pertuzumab to TCH. At Vanderbilt, addition of pertuzumab to TCH chemotherapy adds about 60 
minutes to the total infusion time. With the increase in toxicity related adverse events, we 
hypothesize that the change in time spent in clinic will increase by more than 60 minutes per 
cycle for patients on TCH+P versus patients on TCH. The extent of this increase could 
differentiate it from being merely a desirable change to an ideal change where clinical efficacy is 
increased without significant increase in treatment burden. 
Quantitative assessments of treatment burden may inform patient and provider decisions 
about treatment paths and provide evidence that new treatments increase or decrease patient 
work. We will show how measures of treatment burden related to patient encounters were 
affected by the transitions from Neulasta administered via subcutaneous injection to OBI, and 
from TCH to TCH+P. Overall, the healthcare system should strive to minimize patient treatment 
burden, but at the very least we should strive to better understand the impact of our interventions 
on patient burden.   
4.2. Methods 
4.2.1. Patient cohorts 
We performed a retrospective analysis of treatment burden for early stage breast cancer 
patients who received systemic infusion therapy in the adjuvant or neoadjuvant setting at the 
Vanderbilt University Medical Center (VUMC) between 2005 and 2016.  Breast cancer patients 
were identified by the presence of a respective ICD-9 (174) or ICD-10 (C50) administrative 
billing code in the enterprise data warehouse. Patient chemotherapy treatment protocols were 
identified from the pharmacy information system using a previously developed method(82). The 
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Vanderbilt Institutional Review Board approved this study and granted a waiver of consent since 
we analyzed a large population of patients in aggregate (IRB #151003). 
3.2.2. Comparing therapeutically non-inferior protocols 
We compared the treatment burden of breast cancer patients receiving dose-dense 
doxorubicin and cyclophosphamide (ddAC) chemotherapy with Neulasta administered by one of 
three routes: 1) subcutaneous injection administered in the infusion center 24-72 hours after 
chemotherapy, 2) subcutaneous injection administered at home 24-72 hours after chemotherapy, 
or 3) OBI injection placed on the body in the infusion center on the same day as their 
chemotherapy treatment.    
3.2.3. Comparing a therapeutically superior protocol 
We compared the treatment burden of patients receiving docetaxel, carboplatin, and 
trastuzumab (TCH) versus docetaxel, carboplatin, trastusumab, and pertuzumab (TCH+P) 
therapy.  During this same time period, the Neulasta OBI was also introduced, so we performed a 
sub-set analysis to evaluate any impact this might have had on detecting changes in treatment 
burden between TCH and TCH+P.  
3.2.4. Burden of treatment measures 
We used the same measures developed in chapter 2 to compare the treatment protocols. 
Since we are interested in the complete burden patients experience, we collected data for all 
types of encounters from the start of their first day of chemotherapy to one cycle length 
equivalent after their last cycle date.  
4.3 Results 
Table 4.1 compares the encounter based treatment burden measures between different 
modes of Neulasta administration for breast cancer patients who received ddAC. From January 
	 37	
2005 to September 2016, 559 patients received 1953 cycles of ddAC. Among those cycles, 
Vanderbilt administered 1053 doses of subcutaneous Neulasta by take-home injection, 576 next-
day subcutaneous injections, and 324 OBIs. Cycles where Neulasta was administered by next-
day injection had patients spending about 30 minutes longer in appointments and one additional 
day in clinic per cycle. While much less prominent, cycles where Neulasta was administered by 
take-home injection had slightly less time in clinic than cycles where the OBI was administered. 
Cycles where patients received the subcutaneous injection of Neulasta the next day had a higher 
admission rate than OBI and take-home Neulasta cycles. 
Table 4.1. Summary of treatment burden for ddAC cycles by Neulasta administration. Median 
(IQR). 
 OBI  Next-Day SubQ Take-Home SubQ 
Total number of cycles in group 324 576 1053 
Appointment count 4 (3-5) 4 (4-6) * 3 (3-4) * 
Hours in appointments 3.7 (3.6-4.6) 4.3 (4.1-5.3) * 3.6 (3.3-4.3) * 
Hours waiting between appointments 1.2 (.67-3.0) 1.3 (.67-2.2) 1.7(.67-1.9)  
Total hours in clinic 5.3 (4.5-8.1) 5.9 (4.9-7.5)  5.0 (4,6.2) * 
Unique appointment days 1 (1-2) 2 (2-3) * 1 (1-2)  
Percentage of cycles with admission 3.7% 5.9% 2.3% 
Average hours length of stay per cycle 1.4 3.0 .8 
* Wilcoxon p-value <.001 compared to OBI 
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Figures 4.4 and 4.5. Hours spent in clinic and unique appointment days per cycle by Neulasta 
administration mode for ddAC patients. Figure 4.5 is a sunflower plot where each outlier point is 
one “petal” of the sunflower. 
 
Table 4.2 compares various dimensions of quantitative treatment burden between breast 
cancer patients receiving TCH versus TCH+P. There were 131 patients who received TCH and 
94 patients who received TCH+P from January 2008 to September 2016. 
 
Table 4.2. Summary of treatment burden comparison between patients receiving TCH and 
TCH+P. Median (IQR). 
* Wilcoxon p-value < .001 
 Overall Next-Day SubQ  OBI 
TCH TCH+P TCH TCH+P TCH TCH+P 
Total number of cycles 
in group 
624 476 208 114 16 178 
Appointment Count 4 (3-6) 4 (3-7) 5 (4-7) 5 (4-7) 4 (3-9) 4 (3-6) 
Hours in appointments 4.6 (3.6-6.1)* 6.2 (5.1-8.4) * 
5.1 (4.4-
6.5)* 
6.8 (6.1-
9.0)* 
5.3 (4.6-8.9) 5.7 (4.6-
7.5) 
Hours waiting between 
appointments 
1.4 (.92-2.4) 1.4 (.91-2.7) 1.5 (.91-
2.8) 
1.4 (.92-
2.5) 
1.0 (.60-1.8) 1.4 (.67-
3.6) 
Total hours in clinic 6.2 (5.0-8.3)* 7.9 (6.3-11)* 
6.8 (5.5-
9.3)* 
8.5 (7.3-
11)* 
6.3 (5.4-9.5) 7.8 (6.0-
11.5) 
Unique appointment 
days        
2 (1-3)* 2 (1-3)* 3 (2-4) 3 (2-4) 1.5 (1-4) 2 (1-3) 
Percentage of cycles 
with an admission 
7.0% 1.7% 6.7% 0.9% 56% 1.1% 
Average hours length 
of stay per cycle 
2.6 1.6 3.3 0.1 8.7 .37 
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Figures 4.6 and 4.7. Hours spent in clinic and unique appointment days per cycle for TCH and 
TCH+P patients. 
 
The median cycles where the patients received TCH+P had 90 minutes more appointment 
time and time spent in clinic. However, there was not a noticeable increase in unique 
appointment days as the median cycle for TCH and TCH+P both had two unique appointment 
days. TCH+P had a much lower percentage of cycles where patients were admitted to the 
hospital. These results remained consistent when looking at patients on TCH or TCH+P who 
received subcutaneous Neuasta the day after chemotherapy. However, when narrowing the 
analysis to just cycles where the Neulasta OBI was given, results were inconclusive due to the 
low number of patients who had the OBI with TCH. 
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Figure 4.8. Proportions of ddAC cycles that had Neulasta administered at home, in clinic, and 
via OBI over time.  
 
 
 
Figure 4.9. Proportion of TCH cycles that included and did not include pertuzumab over time. 
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The use of pertuzumab and various Neulasta administrations changed over time. With 
ddAC patients, we first used the OBI in January 2015 and it quickly became the most popular 
method of administering Neulasta. Vanderbilt first used pertuzumab with TCH in May 2012. In 
2013 and after, we used TCH+P much more than TCH for HER2 positive breast cancer patients. 
To get a sense of how the overall burden to the patient changed after each of these changes in 
medical practice, table 4.3 compares the overall treatment burden aggregated by patient before 
and after Vanderbilt introduced the new respective treatment. 
Table 4.3. Overall patient burden before and after the introduction of pertuzumab to TCH and 
the Neulasta OBI to ddAC. Median (IQR). 
 ddAC TCH/P 
Before 1/2015 After 1/2015 Before 
5/2012 
After 5/2012 
Total number of patients in 
group 
441 118 72 153 
Mean number of Cycles 3.5 3.6 4.9 4.9 
Appointment Count 14 (10-17) 15 (12-19) 26 (20-33) 25 (19-31) 
Hours in appointments 15 (12-17) 15 (14-18) 25 (19-31) 32 (21-39) 
Hours waiting between 
appointments 
5.3 (3.0-7.4) 5.3 (3.5-8.6) 9.7 (6.1-13) 9.3 (5.8-13) 
Total hours in clinic 21 (16-24) 22 (18-28) 35 (28-44)  41 (32-53)  
Unique appointment days        7 (4-9) 6 (4-8) 12 (8-17) 10 (7-14) 
Percentage of patients with 
admission 
15% 8% 17% 22% 
Average hours length of stay 7 3 7 12 
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Figure 4.10. Unique appointment days across whole ddAC regimen before and after January 
2015. 
Figure 4.11. Total Time in clinic across whole TCH/P regimen before and after May 2012.  
 
Patients who received ddAC after January 2015 when the OBI was introduced 
experienced one more fewer appointment day across their chemotherapy regimen compared to 
patients on ddAC before January 2015. Patients who received either TCH or TCH+P after May 
2012 when TCH+P was first administered at Vanderbilt experienced six additional hours in 
clinic compared to those who received one of these regimens before May 2012. 
4.4. Discussion 
Results showed that while changes in chemotherapy treatment protocols altered burden 
factors, some of these changes were more nuanced. Patients receiving ddAC with Neulasta 
administered via OBI experienced a decrease in unique appointment days but only a small 
change in the total time spent in clinic. Unique appointment days for ddAC patients with 
Neulasta OBI had one fewer unique appointment day and about 30 minutes less appointment 
time per cycle. Since a next-day Neulasta injection appointment is only 30 minutes long, we did 
not expect to see a significant change in appointment time for OBI patients. These results show 
that the transition to using the OBI use is a desirable change for patients who are concerned 
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about unique appointment days but not as beneficial for patients who want to decrease the time 
spent in clinic. Patients who live far away from the chemotherapy clinic would benefit most from 
the OBI compared to patients who live very close to the medical center who may prefer to come 
into the clinic to get the Neulasta injection from a nurse. Another advantage of the OBI was that 
cycles where Vanderbilt used the OBI had fewer admissions than those of the next-day 
subcutaneous injection. This reduction in admissions could be a result of the more precise timing 
of the Neulasta injection by the OBI or from the decrease in stress to the patient from not having 
to return to the clinic. 
Although the appointment metrics are similar for OBI and take-home injection patients, 
the OBI may provide other burden alleviating benefits. Neulasta is an expensive medication and 
there is an extensive authorization process that the patient must complete. Patients who take 
home Neulasta also have to participate in training on how to properly perform a subcutaneous 
injection or find a healthcare professional in their neighborhood who can help give the injection. 
Additionally, there may be a co-pay for taking home Neulasta that adds to the financial burden of 
care. OBI patients would not need to pay since applying the OBI is part of their chemotherapy 
encounter. 
Although the OBI was effective in reducing the number of days patients have to travel to 
the medical center, there may be some hidden disadvantages of reducing treatment burden. 
Patients who return to the infusion clinic a day or two after their chemotherapy can report any 
adverse reactions to the nursing staff. This built-in follow-up session allows patients to get 
treatment for complications before they get worse. Considering that the rate of admissions and 
emergency room visits did not increase in OBI patients, it does not appear that there were more 
complications with OBI use. Nevertheless, it is important that providers consider patients that 
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may benefit from more visits to the clinic when deciding to prescribe burden alleviating 
treatments like the OBI. 
The addition of pertuzumab to the TCH protocol increased the appointment time and total 
time for appointments by about 90 minutes per cycle but did not significantly increase the wait 
time or the unique appointment days. In addition to looking at TCH and TCH+P patients overall, 
we subsetted those patients into those receiving Neulasta subcutaneously the next day and those 
receiving Neulasta with the OBI, since the mode of Neulasta administration could be a 
confounding variable. We did not include a separate analysis of patients who received Neulasta 
at home since that data was not available in the medication dispensing records. There were only 
10 cycles of TCH patients who received the OBI, but the 90-minute increase in appointment time 
and total time for TCH+P patients was true in the subset of patients receiving subcutaneous 
Neulasta. The finding that the addition of pertuzumab to TCH did not add unique appointment 
days is important for providers to communicate to their patients who may be concerned with 
having to make additional trips to the clinic. However, the 90-minute increase in appointment 
time exceeds the expected 60-minute increase from the increased infusion time. The increased 
appointment time without the increase in unique appointment days shows that complications due 
to increased toxicity of TCH+P may have been handled on days where the patient already had 
other appointments. Based on past evidence that TCH+P is therapeutically superior to TCH, we 
would conclude that adding pertuzumab to TCH is close to an ideal change for patients 
concerned about the work associated with unique appointment days but just a desirable change 
for patients concerned about the total time they spend in clinic. 
One interesting finding was that the percentage of cycles where the patient was admitted 
was less for TCH+P than TCH, despite TCH+P having higher toxicity as discussed previously. 
	 45	
However, when aggregating across patients, we observed that the percentage of patients 
receiving TCH/P who were admitted after pertuzumab was introduced in May 2012 increased by 
5%. This may imply that patients who received TCH after May 2012 were admitted more often 
than TCH patients before May 2012. One explanation for this is that since TCH+P is a newer 
treatment protocol, providers focused more intently on managing TCH+P patients than TCH 
patients after May 2012 resulting in a lower admission rate for TCH+P patients. 
Table 4.3 shows how patient burden changed after the new treatment options were 
introduced. The changes aggregated by patient are less significant compared to the cycle by 
cycle comparison. Since we observed a reduction of one unique appointment day per cycle with 
the OBI compared to the next day subcutaneous injection, we would expect a reduction of three 
to four unique appointment days per patient after the OBI was implemented. However, the 
median patient who received ddAC after the OBI was introduced in January 2015 experienced 
only one fewer unique appointment day over the course of their chemotherapy regimen. There 
are several explanations for the diminished effect. Patients of a given protocol may have 
undergone differing numbers of cycles. Additionally, a patient may have Neulasta administered 
via more than one mode from cycle to cycle. While Neulasta OBI use overtook subcutaneous 
Neulasta quickly, there were still a significant number of cycles after the implementation of the 
new treatment that would have diluted the effect on treatment burden. Furthermore, figure 4.5 
shows that unique appointment days had a long tail on the upward side meaning there were more 
outliers of cycles where patients experienced a high number of unique appointment days. 
Patients receiving ddAC after the OBI was implemented with a cycle that included any of these 
outliers may not have realized the benefit of the OBI in reducing overall unique appointment 
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days across their chemotherapy regimen. The elimination of the next-day infusion would have 
had a small impact on the overall burden for these patients.  
The median TCH/P patient experienced six more hours in clinic after Vanderbilt 
introduced pertuzumab in May 2012. With the observed 90-minute increase per cycle, we would 
expect an increase of 7.5 hours per patient after the first TCH+P administration in May 2012. 
The six hour increase in total time spent in clinic is less than the 7.5 hours expected from the per 
cycle data but still greater than the five hour increase we expect from just added infusion time 
from adding pertuzumab. The six hour increase further supports the hypothesis that increased 
toxicity from pertuzumab may cause patients get more care to address adverse events from their 
chemotherapy. 
4.5 Conclusions 
 In this chapter, we demonstrated treatment burden changes with changes in chemotherapy 
protocols. In our study population, adding pertuzumab to TCH increased the appointment time 
by more than the 60 minutes of increased infusion time, indicating that the increased toxicity led 
to more complications. Due to its therapeutic superiority, the increase in treatment burden made 
the transition from TCH to TCH+P a desirable but not an ideal change. For ddAC patients, 
unique appointment days decreased when VUMC used the OBI showing that the new technology 
succeeded in its goal to reduce treatment burden.  
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CHAPTER 5 
Conclusions and Future Work 
5.1 Conclusions 
Through this study, we sought to introduce the concept of patient burden to the medical 
oncology and informatics communities. We succeeded in developing several measures for 
treatment burden computed from clinical encounter data at Vanderbilt. We applied these 
measures to a population of breast cancer patients and were able to differentiate burden of 
treatment in patients with stage I-III breast cancer. In this population, we observed patterns of 
treatment over time after date of diagnosis. We also used these measures to detect changes in 
burden with adjustments in chemotherapy protocols, revealing that devices designed to decrease 
burden had their intended effect, and that chemotherapy drugs that were highly toxic, while 
therapeutically superior, added to patient burden. 
Therefore, with the measures we developed in this study, we demonstrate a framework 
for three new studies of treatment burden. The first type of study from Chapter 3 is to visualize 
the distribution of treatment burden in a population of patients and to identify outliers who may 
require additional attention. The second type of study, also from Chapter 3, is to track the change 
over time in treatment burden for a patient or population of patients in order to educate patients 
about the impending work associated with their condition, or for healthcare organizations to 
allocate resources required to address future demand. The third type of study from Chapter 4 
compares treatment burden before and after the implementation of an operational or clinical 
practice change. Healthcare organizations and private companies should perform these studies to 
determine the extent to which new treatments increase or decrease burden. 
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5.2 Future Work 
Future work includes incorporating additional factors that influence patient burden 
identified in previous literature. To more accurately capture the patient experience related to 
appointments, we plan to incorporate commute time into their burden assessment by adding the 
time to drive from their home address to the clinic address before and after appointments. We 
will use other structured data such as medication prescriptions to determine the frequency of 
home medication use, and billing information to approximate other medical encounters not 
captured directly as appointments. There is also potential for natural language processing of 
notes to capture other provider recommended activities crucial to outcomes such as exercise or 
diet changes. Complementary to the need for an accurate assessment of a patient’s treatment 
burden is the determination of a patient’s capacity for treatment. With burden and capacity, we 
can compare outcomes for patients for whom burden exceeds capacity against those who receive 
care within their means. 
To extend our work tracking burden with changes in healthcare practice, we plan to 
investigate whether changing from a fee-for-service payment model to a value-based or bundled 
payment model decreases treatment burden. As hypothesized in the introduction, we anticipate 
that incentivizing healthcare systems to decrease costs should result in a decrease in treatment 
burden for patients. The Oncology Care Model program where the Centers for Medicare and 
Medicaid Services (CMS) pays healthcare systems based on episodes of care may present an 
opportunity to make those comparisons in patients with cancer(83). 
We also want to use qualitative methods such as surveys and patient interviews to 
correlate our quantitative measures with patient and caregiver experiences of burden. We plan to 
perform interviews with patients themselves as well as cancer navigators who are healthcare 
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professionals familiar with struggles cancer patients face(84). We also want to present patients, 
providers, and support staff with treatment burden information through electronic media or 
decision support. Observing how members of the healthcare community use this information to 
improve patient care will ultimately determine its impact to society. By better understanding 
burden of treatment, we can begin to deliver precision medicine not only based on genetic 
makeup and disease phenotypes, but also on the patient’s capacity to comply with treatment 
plans in order to maximize the likelihood for improved outcomes. 
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